Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

0.5001
-0.0196-3.77%
Post-market: 0.5000-0.0001-0.02%19:31 EDT
Volume:1.75M
Turnover:903.56K
Market Cap:45.95M
PE:-1.04
High:0.5469
Open:0.5269
Low:0.5000
Close:0.5197
52wk High:3.62
52wk Low:0.4320
Shares:91.88M
Float Shares:63.73M
Volume Ratio:0.75
T/O Rate:2.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4828
EPS(LYR):-0.3800
ROE:-76.14%
ROA:-45.70%
PB:1.20
PE(LYR):-1.32

Loading ...

Context downgraded to Market Perform from Outperform at LifeSci Capital

TIPRANKS
·
Aug 07

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move

Benzinga Earnings
·
Aug 06

Context Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Context Therapeutics Q2 FY26 Net Loss Widens 65% to $14.56 Million Year over Year

Reuters
·
Aug 06

Context Therapeutics Inc. Q2 Net Income USD -14.6 Million

THOMSON REUTERS
·
Aug 06

Context Therapeutics Inc. Q2 Basic EPS USD -0.15

THOMSON REUTERS
·
Aug 06

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

THOMSON REUTERS
·
Aug 06

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

TIPRANKS
·
Aug 01

Context Therapeutics Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Aug 01

Context Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Context Therapeutics Grants New Hire Stock Options for 146,000 Shares at $0.7 Each

Reuters
·
Jul 11

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 11

Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst

TIPRANKS
·
Jul 10

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

THOMSON REUTERS
·
Jul 07

Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million

Reuters
·
Jun 27

Context Therapeutics selloff brings buying opportunity, says JonesResearch

TIPRANKS
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)

TIPRANKS
·
Jun 16

Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright

TIPRANKS
·
Jun 16

Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data

TIPRANKS
·
Jun 15